Citius Pharmaceuticals Inc(CTXR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:25 PM ET (Korea 11/7 06:25)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.11 | Insider Own | 1.8% | Shs Outstand | 27.4M | Perf Week | 4.21% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 29.06% | Insider Trans | - | Shs Float | 27.0M | Perf Month | 11.54% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.41 | Inst Own | 5.16% | Short Float | 21.14% | Perf Quarter | -19.48% |
| Income | -0.05B | P/S | 2.1 | EPS this Y | 39.94% | Inst Trans | -2.81% | Short Ratio | 14.54 | Perf Half Y | -14.83% |
| Sales | 0.01B | P/B | 0.22 | EPS next 5Y | 41.69% | ROA | -34.29% | Short Interest | 5.70M | Perf YTD | -29.85% |
| Book/sh | 2.43 | P/C | 0.88 | EPS past 3/5Y | 16.24% 21.29% | ROE | -70.29% | 52W High | -64.6% ($1.54) | Perf Year | -56.04% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | -62.86% | 52W Low | 47.36% ($0.37) | Perf 3Y | -97.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.48% | Gross Margin | 19.97% | Volatility(W/M) | 13.21% 11.31% | Perf 5Y | -98.88% |
| Dividend TTM | - | EV/Sales | 2.03 | Sales Y/Y TTM | - | Oper. Margin | -863.92% | ATR (14) | 0.06 | Perf 10Y | -99.72% |
| Dividend Ex-Date | - | Quick Ratio | 0.4 | EPS Q/Q | 57.59% | Profit Margin | -651.27% | RSI (14) | 55.09 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.84 | Sales Q/Q | - | SMA20 | 11.98% ($0.49) | Beta | 0.99 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/8/14 | SMA50 | 2.56% ($0.54) | Rel Volume | 0.51 | Prev Close | $0.56 |
| Employees | 23 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 5.56% -72.64% | SMA200 | -16.14% ($0.66) | Avg Volume(3M) | 0.39M | Price | $0.55 |
| IPO | 2014/10/2 | Option/Short | Yes/Yes | Trades | 431 | Volume | 199,839 | Change | -2.21% |
💊 A small pharmaceutical company currently selling LYMPHIR, a novel lymphoma drug, in the early commercialization stage. Its subsidiary, Citius Oncology (CTOR), handles the oncology pipeline, while the parent company, CTXR, holds late-stage clinical assets such as Mino-Lok® (a catheter infection prevention agent) and Halo-Lido (a hemorrhoid treatment). It is a diversified, mixed-stage small-cap biopharma spanning clinical development and commercialization.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
CTXR has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $210. Peers typically go for $917.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.9%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #481 of 597 in the industry
Based on market cap of $15M.
KYNB#478 Kyntra Bio Inc $15M PER 0.1 
RADX#479 Radiopharm Theranostics Ltd ADR $15M PER - 
NEUP#480 Neuphoria Therapeutics Inc $15M PER - CTXR#481 Citius Pharmaceuticals Inc $15M PER - 
MRKR#482 Marker Therapeutics Inc $15M PER - 
FAQ
What kind of company is CTXR?
CTXR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CTXR?
The market cap of CTXR is approximately $15M, ranking 5,287 within its sector.
What is the 52-week high and low for CTXR?
CTXR has recorded a 52-week high of $1.54 and a low of $0.37.
